MEDI Harbor Health Care ETF
ETF on NYSE (US) · Actively managed · Listing
Changes appear once four weeks of holdings are on file.
Largest holding: Eli Lilly and Company, 6,543 shares ($9.33M).
| Current positions Top 10 | % of book |
|---|---|
| Eli Lilly and Company LLY $9.33M | 21.4% |
| Ascendis Pharma A/S ASND $7.47M | 17.1% |
| argenx SE ARGX $2.24M | 5.1% |
| Vaxcyte, Inc. PCVX $1.53M | 3.5% |
| Guardant Health, Inc. GH $1.48M | 3.4% |
| Insmed Incorporated INSM $1.37M | 3.1% |
| Rhythm Pharmaceuticals, Inc. RYTM $1.37M | 3.1% |
| United Therapeutics Corporation UTHR $1.32M | 3.0% |
| Revolution Medicines, Inc. RVMD $1.19M | 2.7% |
| IDEXX Laboratories, Inc. IDXX $1.11M | 2.6% |
Slices are % of holdings value.
| Sectors | % of holdings value |
|---|---|
| Healthcare | 98.4% |
| Financial Services | 1.6% |
| Industries | % of holdings value |
|---|---|
| Biotechnology | 53.9% |
| Drug Manufacturers - General | 24.0% |
| Diagnostics & Research | 5.5% |
| Medical Devices | 3.8% |
| Medical Distribution | 3.1% |
| Medical Instruments & Supplies | 2.6% |
| Healthcare Plans | 1.7% |
| Other (4) | 5.5% |
Source: the fund's own published holdings, the portfolio of Nov 12, 2026 (harborcapital.com). Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the summary prospectus filed Feb 27, 2026.
The Fund seeks long-term growth of capital.
Principal investment strategies
The Fund invests primarily in equity securities, principally common and preferred stocks of companies of any market capitalization. Under normal market conditions, the Fund invests at least 80% of its net assets, plus borrowings for investment purposes, in securities of companies principally engaged in the research, development, production, or distribution of products and services related to the health care industry ("health care companies"). Health care companies may include, for example, manufacturers of health care equipment and supplies, health care services providers, pharmaceutical companies, biotechnology and life sciences companies, and suppliers of technologies for use by health care companies. The Fund may invest in issuers of all market capitalizations, including larger, established issuers and newer companies with little or no current revenues. The Fund may invest in foreign securities (including through investment in depositary receipts), with such investments typically representing less than 35% of the Fund's net assets. Westfield Capital Management, Company, L.P. ("Westfield" or the "Subadvisor"), the Fund's subadvisor, uses a bottom-up process to identify primarily U.S. listed health care companies that meet the Subadvisor's strict fundamental criteria and then performs a qualitative review on each identified company to select approximately 30 to 50 companies for inclusion in the Fund's portfolio. The Subadvisor considers a number of factors in the course of its fundamental research, including but not limited to valuation, competitive advantage, market opportunity, financial metrics, capital structure, and management track record of execution. The Subadvisor's research may include personal interviews and other contact with company management. In constructing the Fund's portfolio, the Subadvisor seeks to identify health care companies that it believes possess the following characteristics: ■ Superior company management; ■ Corporate governance that aligns with shareholder value creation; ■ Unique market positions and broad market opportunities; and ■ Solid financial controls and accounting processes. The Subadvisor may sell a security if the security reaches or falls below a predetermined price target, a change in the company's fundamentals negatively impacts the Subadvisor's original investment thesis, or the Subadvisor identifies what it believes to be a more attractive investment opportunity. The Fund is classified as non-diversified, which means the Fund may invest in the securities of a smaller number of issuers than a diversified fund. 1 Summary Prospectus Harbor Health Care ETF The Fund concentrates its investments (i.e., holds more than 25% of its total assets) in the securities of issuers in the health care industry or group of industries.
Management and Contact
- Adviser
- Harbor Capital Advisors, Inc.
- Sub-adviser
- Westfield Capital Management, Company, L.P.
- Portfolio managers
-
The portfolio managers are jointly and primarily responsible for the day-to-day investment decision making for the Fund.
William A. Muggia Westfield Capital Management Company, L.P. Mr. Muggia is the President, Chief Investment Officer, Chief Executive Officer, a Portfolio Manager and Managing Partner of Westfield and has co-managed the Fund since 2022.
Matthew R. Renna Westfield Capital Management Company, L.P. Mr. Renna is a Partner, Head of the Health Care Sector Team, and a Portfolio Manager of Westfield and has co-managed the Fund since 2022.
- Phone
- 800-422-1050
- [email protected]
Track Record as of Dec 31, 2025
Average annual total returns from the summary prospectus. Returns in percent; periods over a year are annualized.
| 1 Year | Since Inception | |
|---|---|---|
| Russell 3000® Growth Health Care Index^^ | 21.87% | 13.50% |
| S&P 500 Index^ | 17.88% | 20.88% |
Holdings as of Nov 12, 2026
The full portfolio the fund publishes every business day on its website (harborcapital.com). Every line is listed: holdings we could identify link to their page, the rest (cash, options, swaps, private shares, securities we do not carry) are shown as the fund prints them. Short positions are negative.
46 lines, 45 linked, weights sum to 100.00% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Weight | Market value |
|---|---|---|---|---|---|
| ELI LILLY & CO | LLY 532457108 | Equity | 6,543 | 21.10% | $ 9.327M |
| ASCENDIS PHARMA A/S | ASND 04351P101 | Equity | 27,953 | 16.90% | $ 7.465M |
| ARGENX SE - ADR | ARGX 04016X101 | Equity | 2,285 | 5.10% | $ 2.242M |
| VAXCYTE INC | PCVX 92243G108 | Equity | 23,584 | 3.50% | $ 1.526M |
| GUARDANT HEALTH INC | GH 40131M109 | Equity | 9,568 | 3.40% | $ 1.482M |
| INSMED INC | INSM 457669307 | Equity | 11,610 | 3.10% | $ 1.371M |
| RHYTHM PHARMACEUTICALS INC | RYTM 76243J105 | Equity | 12,452 | 3.10% | $ 1.368M |
| UNITED THERAPEUTICS CORP | UTHR 91307C102 | Equity | 2,231 | 3.00% | $ 1.324M |
| REVOLUTION MEDICINES INC | RVMD 76155X100 | Equity | 6,739 | 2.70% | $ 1.188M |
| IDEXX LABORATORIES INC | IDXX 45168D104 | Equity | 1,591 | 2.50% | $ 1.111M |
| CENCORA INC | COR 03073E105 | Equity | 2,736 | 2.20% | $ 954.098K |
| UNITEDHEALTH GROUP INC | UNH 91324P102 | Equity | 1,867 | 1.70% | $ 756.378K |
| NATERA INC | NTRA 632307104 | Equity | 2,321 | 1.70% | $ 749.544K |
| SUPERNUS INC | SUPN 45579U109 | Equity | 25,554 | 1.70% | $ 746.177K |
| ABBVIE INC | ABBV 00287Y109 | Equity | 2,420 | 1.60% | $ 712.569K |
| ABIVAX SA-ADR | ABVX 00370M103 | Equity | 7,743 | 1.60% | $ 698.419K |
| HEALTHEQUITY INC | HQY 42226A107 | Equity | 6,662 | 1.60% | $ 686.519K |
| INTUITIVE SURGICAL INC | ISRG 46120E602 | Equity | 1,541 | 1.50% | $ 677.87K |
| PTC THERAPEUTICS INC | PTCT 69366J200 | Equity | 9,930 | 1.40% | $ 629.165K |
| DANAHER CORP | DHR 235851102 | Equity | 2,524 | 1.30% | $ 585.972K |
| GLAUKOS CORP | GKOS 377322102 | Equity | 2,248 | 1.30% | $ 553.075K |
| XENON PHARMACEUTICALS INC | XENE 98420N105 | Equity | 13,433 | 1.20% | $ 550.686K |
|
Cash and Other Assets Less Liabilities
|
Cash | — | 1.10% | — | |
| LEGEND BIOTECH CORP-ADR | LEGN 52490G102 | Equity | 24,327 | 1.00% | $ 451.023K |
| VERTEX PHARMACEUTICALS INC | VRTX 92532F100 | Equity | 817 | 1.00% | $ 443.321K |
| IRHYTHM HOLDINGS INC | IRTC 450056106 | Equity | 4,641 | 1.00% | $ 434.212K |
| AXSOME THERAPEUTICS INC | AXSM 05464T104 | Equity | 2,908 | 1.00% | $ 419.828K |
| VIATRIS INC | VTRS 92556V106 | Equity | 19,123 | 0.90% | $ 395.272K |
| MCKESSON CORP | MCK 58155Q103 | Equity | 363 | 0.90% | $ 390.969K |
| PRAXIS PRECISION MEDICINES I | PRAX 74006W207 | Equity | 1,173 | 0.90% | $ 380.943K |
| RADNET INC | RDNT 750491102 | Equity | 4,944 | 0.90% | $ 375.942K |
| TANGO THERAPEUTICS INC | TNGX 87583X109 | Equity | 14,086 | 0.80% | $ 350.037K |
| ENLIVEN THERAPEUTICS INC | ELVN 29337E102 | Equity | 6,976 | 0.80% | $ 337.011K |
| ORUKA THERAPEUTICS INC | ORKA 687604108 | Equity | 3,145 | 0.70% | $ 330.194K |
| SPYRE THERAPEUTICS INC | SYRE 00773J202 | Equity | 3,207 | 0.70% | $ 330.032K |
| RELAY THERAPEUTICS INC | RLAY 75943R102 | Equity | 13,489 | 0.60% | $ 243.881K |
| DIANTHUS THERAPEUTICS INC | DNTH 252828108 | Equity | 2,487 | 0.50% | $ 229.998K |
| BRIGHTSPRING HEALTH SERVICES | BTSG 10950A106 | Equity | 3,128 | 0.50% | $ 223.496K |
| PALVELLA THERAPEUTICS INC | PVLA 697947109 | Equity | 1,455 | 0.50% | $ 222.877K |
| ERASCA INC | ERAS 29479A108 | Equity | 13,905 | 0.50% | $ 221.929K |
| ADAPTIVE BIOTECHNOLOGIES | ADPT 00650F109 | Equity | 7,323 | 0.50% | $ 215.882K |
| KRYSTAL BIOTECH INC | KRYS 501147102 | Equity | 656 | 0.50% | $ 200.526K |
| SOPHIA GENETICS SA | SOPH H82027105 | Equity | 23,315 | 0.40% | $ 183.256K |
| 10X GENOMICS INC-CLASS A | TXG 88025U109 | Equity | 2,889 | 0.40% | $ 170.74K |
| HEALTH CATALYST INC | HCAT 42225T107 | Equity | 119,131 | 0.40% | $ 162.018K |
| INVENTIVA SA - ADR | IVA 46124U107 | Equity | 32,662 | 0.30% | $ 126.729K |
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up